ABEO
Abeona Therapeutics Inc
5.00$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 86.6% | 87.1% | 89.2% | 94.0% | 93.4% | 92.6% | 88.7% | 94.3% | 93.5% | 93.3% | 92.2% | 91.7% | |
| 7.1% | 22.6% | 23.5% | 25.7% | 13.0% | 21.4% | 16.0% | 66.4% | 36.0% | 35.7% | 30.9% | 31.3% | |
| 81.3% | 81.6% | 83.3% | 91.6% | 91.0% | 89.7% | 84.7% | 91.6% | 89.8% | 87.2% | 84.8% | 81.8% | |
| 3.3% | 3.8% | 3.0% | 1.2% | 1.3% | 1.5% | 1.6% | 0.7% | 0.7% | 3.1% | 3.4% | 5.5% | |
| 0.5% | – | – | – | – | 0.0% | – | 1.1% | 2.1% | 2.5% | 3.0% | 3.3% | |
| 13.1% | – | – | – | – | – | – | – | – | – | – | – | |
| 66.7% | 76.8% | 111.9% | 45.3% | 62.0% | 59.6% | 58.3% | 33.6% | 25.9% | 27.5% | 27.0% | 28.7% | |
| 12.7% | 21.0% | 15.9% | 12.6% | 15.3% | 15.2% | 18.1% | 14.0% | 9.6% | 13.5% | 15.6% | 13.8% | |
| 2.5% | 1.6% | 1.4% | 3.0% | 4.6% | 6.2% | 8.8% | 2.5% | 3.9% | 6.0% | 7.4% | 8.1% | |
| 3.9% | 2.9% | 4.5% | 2.3% | 2.3% | 3.2% | 5.1% | 3.0% | 2.6% | 3.6% | 2.1% | 1.7% | |
| – | – | 24.2% | 12.0% | 11.8% | 12.0% | 11.2% | 5.7% | 4.7% | 3.6% | 2.4% | 0.9% | |
| 33.3% | 23.2% | -11.9% | 54.7% | 38.0% | 40.4% | 41.7% | 66.4% | 74.1% | 72.5% | 73.0% | 71.3% | |
| -1,109.0% | -1,171.1% | -1,043.9% | -577.4% | -666.7% | -746.6% | -830.6% | -291.0% | -312.3% | -338.0% | -382.5% | -434.2% | |
| 37.5% | 39.9% | 36.5% | 38.2% | 39.9% | 37.7% | 50.1% | 27.1% | 23.5% | 30.1% | 28.5% | 31.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.